The outbreak of a severe acute respiratory syndrome caused by a novel coronavirus (COVID-19), has raised health concerns for patients with multiple sclerosis (MS) who are commonly on long-term immunotherapies. Managing MS during the pandemic remains challenging with little published experience and no evidence-based guidelines. We present five teriflunomide-treated patients with MS who subsequently developed active COVID-19 infection. The patients continued teriflunomide therapy and had self-limiting infection, without relapse of their MS. These observations have implications for the management of MS in the setting of the COVID-19 pandemic.
COVID-19 in teriflunomide-treated patients with multiple sclerosis / Maghzi, A. H.; Houtchens, M. K.; Preziosa, P.; Ionete, C.; Beretich, B. D.; Stankiewicz, J. M.; Tauhid, S.; Cabot, A.; Berriosmorales, I.; Schwartz, T. H. W.; Sloane, J. A.; Freedman, M. S.; Filippi, M.; Weiner, H. L.; Bakshi, R.. - In: JOURNAL OF NEUROLOGY. - ISSN 0340-5354. - 267:10(2020), pp. 2790-2796. [10.1007/s00415-020-09944-8]
COVID-19 in teriflunomide-treated patients with multiple sclerosis
Preziosa P.;Filippi M.;
2020-01-01
Abstract
The outbreak of a severe acute respiratory syndrome caused by a novel coronavirus (COVID-19), has raised health concerns for patients with multiple sclerosis (MS) who are commonly on long-term immunotherapies. Managing MS during the pandemic remains challenging with little published experience and no evidence-based guidelines. We present five teriflunomide-treated patients with MS who subsequently developed active COVID-19 infection. The patients continued teriflunomide therapy and had self-limiting infection, without relapse of their MS. These observations have implications for the management of MS in the setting of the COVID-19 pandemic.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
